Key Drivers
- Margin recovery
- Positive cash flow
- Elevated leverage
AIAI Summary
Baxter is evolving into a turnaround-and-deleveraging opportunity, but investors should wait for evidence that Infusion Systems recovery and margin gains can replace 2026's temporary tariff and TSA benefits before treating the oversold shares as a durable value entry.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin recovery
- •Positive cash flow
- •Elevated leverage
BAX's profitability and cash flow have rebounded, but high leverage, intangible-heavy assets, and elevated valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Persistent selling
- •Oversold RSI
BAX fell 13.6% over the last month, remaining bearish below its average despite oversold rebound potential; watch $22.80 support and $23.80–$24.18 resistance.
Sharp 13.6% decline over the last month
Sentiment & News
Key News Insights:
- •Raised 2026 outlook
- •Institutional buying
- •Persistent cost pressures
Baxter's raised 2026 outlook and growing institutional ownership signal improving momentum, though margin pressure from costs, tariffs, and pricing remains a key risk.
The outlook upgrade supports a constructive near-term view for BAX, but margin headwinds may limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings